Clinical trials of CAR-T cells in China

Article English OPEN
Bingshan Liu ; Yongping Song ; Delong Liu (2017)
  • Publisher: BMC
  • Journal: Journal of Hematology & Oncology, volume 10 (issn: 1756-8722, eissn: 1756-8722)
  • Related identifiers: doi: 10.1186/s13045-017-0535-7, pmc: PMC5651613
  • Subject: Rapid Communication | Diseases of the blood and blood-forming organs | RC254-282 | RC633-647.5 | Neoplasms. Tumors. Oncology. Including cancer and carcinogens
    mesheuropmc: human activities

Abstract Novel immunotherapeutic agents targeting tumor-site microenvironment are revolutionizing cancer therapy. Chimeric antigen receptor (CAR)-engineered T cells are widely studied for cancer immunotherapy. CD19-specific CAR-T cells, tisagenlecleucel, have been recently approved for clinical application. Ongoing clinical trials are testing CAR designs directed at novel targets involved in hematological and solid malignancies. In addition to trials of single-target CAR-T cells, simultaneous and sequential CAR-T cells are being studied for clinical applications. Multi-target CAR-engineered T cells are also entering clinical trials. T cell receptor-engineered CAR-T and universal CAR-T cells represent new frontiers in CAR-T cell development. In this study, we analyzed the characteristics of CAR constructs and registered clinical trials of CAR-T cells in China and provided a quick glimpse of the landscape of CAR-T studies in China.
Share - Bookmark